Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2022 Jun;82(8):925-931. doi: 10.1007/s40265-022-01723-1.
Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers. Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolumab targeting the programmed cell death protein 1 (PD-1) receptor and relatlimab being a newly developed, first-in-class drug targeting the lymphocyte-activation gene 3 (LAG-3) protein. In March 2022, nivolumab plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg. This article summarizes the milestones in the development of this combination therapy leading to this first approval for unresectable or metastatic melanoma.
纳武利尤单抗联合雷利度胺（纳武利尤单抗和雷利度胺-rmbw；Opdualag）是百时美施贵宝公司开发的一种固定剂量、联合免疫疗法，用于治疗多种类型的晚期癌症。这两种药物都是免疫球蛋白 G4（IgG4）单克隆抗体，旨在针对免疫检查点，纳武利尤单抗针对程序性死亡蛋白 1（PD-1）受体，雷利度胺是一种新开发的、首创的靶向淋巴细胞激活基因 3（LAG-3）蛋白的药物。2022 年 3 月，纳武利尤单抗联合雷利度胺在美国首次获批用于治疗不可切除或转移性黑色素瘤的成年患者和≥40kg 体重的≥12 岁儿科患者。本文总结了这一联合疗法开发过程中的重要里程碑，最终促成了该药物在不可切除或转移性黑色素瘤方面的首次获批。
